Form 4: Gyre Therapeutics President Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Songjiang Ma, President of Gyre Therapeutics, sold 4,000 shares of common stock on December 30 and 31, 2024, under a pre-arranged trading plan.
Summary
- Songjiang Ma, President of Gyre Therapeutics, sold 2,000 shares of common stock on December 30, 2024, at a weighted average price of $12.50 per share.
- An additional 2,000 shares were sold on December 31, 2024, at a weighted average price of $12.30 per share.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.
- Following these sales, Ma directly owns no shares, but indirectly owns 2,922,467 shares through their spouse.
Sentiment
Score: 5
Explanation: The document is a routine disclosure of stock sales under a pre-arranged trading plan, indicating a neutral sentiment.
Industry Context
Sales by company presidents are common and are often pre-planned to avoid insider trading accusations. The use of a 10b5-1 plan is a standard practice.
Stakeholder Impact
- The stock sales may have a minor impact on shareholders, but the pre-planned nature of the transactions mitigates concerns about insider trading.
Key Dates
| Date | Description |
|---|---|
| 09/13/2024 | Date of adoption of Rule 10b5-1 trading plan |
| 12/30/2024 | Date of first stock sale (2,000 shares) |
| 12/31/2024 | Date of second stock sale (2,000 shares) |
| 01/02/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.